PHARMACY

Teva launches generic version of Prometrium

BY Allison Cerra

JERUSALEM — A generic drug maker has launched its version of an Abbott Labs drug.

Teva Pharmaceutical Industries said it launched progesterone capsules in the 100-mg and 200-mg strengths, a generic version of Prometrium.

Prometrium is indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogen tablets. The drug also is indicated for use in secondary amenorrhea.

For the 12 months ended Jan. 31, Prometrium had sales of approximately $198 million, according to IMS Health data.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Independent Pharmacy Cooperative joins RxAlly

BY Alaric DeArment

SUN PRAIRIE, Wis. — An organization representing independent pharmacies has joined a recently announced nationwide pharmacy network that aims to get patients to receive personalized care from their pharmacists.

The Independent Pharmacy Cooperative, which represents some 4,000 stores, announced that it had joined the RxAlly network, which includes more than 20,000 pharmacies across the country and whose membership includes independent pharmacy groups, regional chains and Walgreens. The network’s launch was announced Feb. 22 with the stated goal of improving patient health outcomes and reducing costs. American Associated Pharmacies, which represents about 2,000 independent pharmacies, also has joined.

"Independent pharmacies struggle every day to maintain their bottom line while trying to focus on their patients," IPC president and CEO Don Anderson said. "They must deal with increasing pressures from government regulations, reimbursements, payer sources and more while searching for ways to improve the outcomes of their patients and to control increase healthcare costs."


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

NACDS’ Nicholson testifies before House panel, highlights pharmacy’s commitment to curbing Rx diversion, abuse

BY Antoinette Alexander

ALEXANDRIA, Va. — The National Association of Chain Drug Stores on Thursday testified before the House of Representatives’ Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade to emphasize retail pharmacy’s commitment to preserving patient safety and high-quality care.

NACDS’ Kevin Nicholson, a registered pharmacist and NACDS’ VP government affairs and pharmacy advisor, testified before the subcommittee during its hearing titled “Prescription Drug Diversion: Combating the Scourge.”

Nicholson emphasized chain pharmacies’ “zero tolerance” for prescription drug diversion.  In his comments he stated, “We have implemented a variety of extensive and robust loss prevention and internal security systems, from our prescription drug distribution centers to point of dispensing to patients.”

He cited examples, including the use of camera surveillance and complex alarm systems, training employees how to handle suspicious prescriptions and conducting background checks and random drug testing for employees.

Nicholson also highlighted chain pharmacies’ participation in state prescription drug monitoring programs.

“We support policies to prevent illegitimate Internet drug sellers from illegally selling prescription drugs to consumers, and we support efforts to provide consumers with means for the proper disposal of unwanted medications in ways authorized by law enforcement,” Nicholson stated before the panel.

As reported by Drug Store News, NACDS earlier in the week endorsed H.R. 4095, “The Online Pharmacy Safety Act,” which it says would take important steps to shut down illegitimate Internet drug sellers.

In his testimony, Nicholson also cited NACDS’ engagement with the Drug Enforcement Administration on diversion trends and to assist in developing strategies to mitigate and reduce problems.

“For the ultimate good of patients who rely on access to controlled substances for legitimate purposes, such as pain management, we urge DEA to take a holistic approach when developing policies to pursue enforcement actions,” Nicholson stated.

NACDS stated that it is highly engaged in efforts to remedy this problem, working with the Food and Drug Administration to develop prescription drug risk management programs, called REMS, to reduce the potential for addiction and abuse of prescription drugs; as well as routinely meeting with the White House Office of National Drug Control Policy, on trends and solutions.

Summarizing NACDS’ commitment to finding solutions to combat prescription drug diversion and abuse, Nicholson stated, “We are proud of the comprehensive approach that chain pharmacies have taken, and look forward to continuing our work with federal and state policymakers to implement solutions, including expanding prescription drug monitoring programs, shutting down illegitimate Internet sites, and providing consumers with the ability to safely dispose unwanted prescription drugs.” 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?